Ciphergen Faces Nasdaq Delisting for Low Market Cap
The Nasdaq exchange told Ciphergen Biosystems last week that it risks being delisted because its market cap has remained below $50 million for 10 consecutive business days.
Ciphergen this week said it has until June 23 to regain compliance. Its market cap currently stands at $41.4 million, according to Nasdaq.
Bruker, Protein Discovery to Co-Market Imaging Mass-Spec Products